This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LUMO Lumos Pharma (LUMO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Lumos Pharma Stock (NASDAQ:LUMO) 30 days 90 days 365 days Advanced Chart Get Lumos Pharma alerts:Sign Up Key Stats Today's Range$4.34▼$4.3450-Day Range$4.30▼$4.4152-Week Range$1.37▼$4.58VolumeN/AAverage Volume75,475 shsMarket Capitalization$37.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.63Consensus RatingBuy Company OverviewLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Read More… Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LUMO Stock News HeadlinesLumos House is Back in Austin: Exclusive Events for Founders and BuildersMarch 4, 2025 | reuters.comLumos Pharma Completes Merger and Delisting ProcessDecember 12, 2024 | tipranks.comYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands of tons of gold locked away in Fort Knox. But there hasn't been an independent audit in over 50 years—and now, both Elon Musk and former Congressman Ron Paul are demanding answers.May 6, 2025 | Hamilton Gold Group (Ad)Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos PharmaDecember 12, 2024 | globenewswire.comLumos Pharma reports sustained growth in PGHD trialsNovember 23, 2024 | uk.investing.comLumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trialsNovember 21, 2024 | markets.businessinsider.comHold Rating on Lumos Pharma Amid Financial Challenges and Strategic Merger with Double Point VenturesNovember 10, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMONovember 6, 2024 | globenewswire.comSee More Headlines LUMO Stock Analysis - Frequently Asked Questions How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.34. The business earned $0.73 million during the quarter, compared to analyst estimates of $0.50 million. Lumos Pharma had a negative trailing twelve-month return on equity of 233.03% and a negative net margin of 1,583.49%. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE). Company Calendar Last Earnings11/07/2024Today5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LUMO CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$8.63 High Stock Price Target$13.00 Low Stock Price Target$4.25 Potential Upside/Downside+98.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,030,000.00 Net Margins-1,583.49% Pretax Margin-1,583.49% Return on Equity-233.03% Return on Assets-129.88% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual Sales$2.21 million Price / Sales17.02 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book1.26Miscellaneous Outstanding Shares8,649,000Free Float6,452,000Market Cap$37.54 million OptionableNot Optionable Beta0.74 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:LUMO) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.